• Home
  • Patient Portals
  • Pay My Bill
  • For Health Professionals
  • Newsroom
  • Contact Us
Willis-Knighton Health System
  • Facebook
  • Instagram
  • YouTube
  • LinkedIn
  • WKHS Home
  • Find A Doctor
  • Services
  • Locations
  • Patients & Visitors
  • Classes & Events
  • Health Resources
  • Careers
  • About Us
  • Patient Portals
  • Pay My Bill
  • For Health Professionals
  • Contact Us

Clinical Trials

Clinical Trials
Home / Clinical Trials / List

Clinical Trials

  • Academic Research
  • Contact Information
  • Clinical Trials Home
  • Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade Serous or High-Grade Endometrioid Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 1 Prior Line of Chemotherapy

    To determine the clinical effectiveness of Lynparza (olaparib) treatment in patients with recurrent ovarian cancer.

  • A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (EMERALD-2)

    To assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab monotherapy or placebo as adjuvant therapy. This study will be conducted in patients with HCC who are at high risk of recurrence after curative hepatic resection or ablation. 888 patients will be enrolled globally.

  • Phase 3 Randomized Trial Comparing Overall Survival After Photon versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB Non-Small Cell Lung Cancer (NSCLC)

    To compare the good and bad effects in terms of patient life span after these 2 different types of radiation therapy (photon versus proton) in combination with FDA-approved chemotherapy for lung cancer. This study will allow the researchers to know whether the proton therapy approach is better, the same, or worse then the usual photon approach in terms of survival.

  • A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma

    To compare the efficacy of TACE with Duravalumab + Bevacizumab, TACE with Duravalumab alone and TACE only.

  • FORWARD 1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator’s Choice of Chemotherapy in Women with Folate Receptor a-positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer

    To compare the progression free survival (PFS) of patients randomized to IMGN853 versus selected standard of care chemotherapy (IC

  • Phase 2 Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer

    To test whether bupropion, a medication that is approved for depression and smoking cessation, can improve sexual desire compared to placebo

  • Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC)

    To obtain information on the safety & effectiveness of the NovoTTF-100M (study device) in patients with brain metastases (tumors) from non-small cell lung cancer.

  • Prospective Research Assessments in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

    To examine how multiple myeloma is treated by doctors all over the world, how people respond to these treatments, & the economic impact of these treatments

  • 14.0012 - Evaluation Tracking Project: A Prospective Chart Review of Patients Treated with Radiation Therapy

    To collect & analyze information on people with similar cancer diagnosis. The effectiveness of procedures & treatments, the usefulness of various tests, and the incidence of short or long-term side effects will be evaluated. The ultimate goal is to improve effectiveness of treatments & procedures & limit side effects & late complications for patients.

  • 16.0001 - Pragmatic Phase III Randomized Trial of Proton versus Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial

    To compare 2 types of standard care radiation treatment: photon and proton, to find out which type is best for treating non-metastatic breast cancer.

  • 15.0007 - Phase 3 Randomized, Double-blind, Placebo Controlled, Multicenter Study to Compare the Efficacy & Safety of Lenalidomide Plus R-CHOP Chemotherapy (R2-CHOP) versus Placebo Plus R-CHOP Chemotherapy in Subjects with Previously Untreated Activated B-Cell (ABC) Type Diffuse Large B-Cell Lymphoma (DLBCL). (The “ROBUST” Study)

    To evaluate the effectiveness & safety of lenalidomide, rituximab, cyclophosphamide, doxorubicin, vincristine, & prednisone (R2-CHOP) chemotherapy versus placebo, rituximab, cyclophosphamide, doxorubicin, vincristine, & prednisone (placebo-R-CHOP) chemotherapy in people who have previously untreated ABC type DLBCL

  • An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas

    The primary objective of this study is to evaluate the efficacy of the regimen of irinotecan liposome injection + oxaliplatin + 5-fluorouracil (5-FU)/leucovorin (LV) versus nab-paclitaxel + gemcitabine in improving overall survival (OS) in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas.

  • 17.0008 - A Pivotal, Double-blind, Randomized, Placebo-controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck

    To test the safety & efficacy of SGX942 in any resulting oral mucositis in patients with squamous cell carcinoma of the head and neck who will also receive treatment with chemotherapy and radiation therapy

  • A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-paclitaxel versus Placebo plus Carboplatin-paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer

    Determine the efficacy and safety of dostarlimab plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel in patients with recurrent or primary advanced (Stage III or IV) endometrial cancer.

  • A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 & 6 Inhibitor, in Combination with Fulvestrant Compared to Chemotherapy in Women with HR Positive, HER2 Negative Metastatic Breast Cancer with Visceral Metastases

    To compare the efficacy of abemaciclib in combination with fulvestrant to that of physician’s choice of chemotherapy in patients with HR+, HER2- metastatic breast cancer with at least 1 site of visceral metastases & at least 1 line of prior Endocrine Therapy.

  • A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically-applied AG013 for the attenuation of oral mucositis in subjects with cancers of the head and neck receiving concomitant chemoradiation therapy.

    To determine the effectiveness as well as safety & tolerability of AG013 in altering the onset, course & severity of oral mucositis compared to placebo (a mouth rinse which looks exactly the same as AG013 but which dose not contain AG013) when administered 3 times each day.

  • A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (3000-03-005/ENGOT-OV44)

    To compare the progression-free survival (PFS) of patients with Stage III or IV ovarian cancer treated with platinum-based therapy, TSR-042, and niraparib to standard-of-care (SOC) platinum-based therapy.

  • informCLL: A Disease Registry for Patients with Chronic Lymphocytic Leukemia

    To describe current treatment patterns in the real-world setting among CLL patients who are beginning treatment with approved oral kinase inhibitors or other approved anti-CLL therapies/regimens as well as any association with patient characteristics, healthcare resource utilization, clinical outcomes, & patient-reported outcomes.

  • Observational Study of Patients with Polycythemia Vera in U.S. Clinical Practices (REVEAL)

    To describe the clinical burden, healthcare resource utilization, complications, practice patterns, and therapy strategies in patients treated for PV in academic & community clinical practices within the United States.

  • 20.0004 - The COVID-19 and Cancer Consortium (CCC19) Registry

    To collect granular information on cancer patients infected with COVID-19.

  • An intermediate access protocol for selumetinib for treatment of neurofibromatosis type 1 with inoperable, progressive/symptomatic plexiform neurofibromas

    To provide access to selumetinib to people with neurofibromatosis type 1 (NF1) with plexiform neurofibromas that cannot be operated on.

  • A Prospective Comparative Study of Outcomes with Proton and Photon Radiation in Prostate Cancer (COMPPARE)

    To determine if prostate cancer patients treated with proton therapy, as compared to IMRT, experience:

    Improved quality of life

    Reduced toxicity

    Non-inferior or even superior cancer control

    To determine if Hypofractionated proton therapy is non-inferior to standard fractionated proton therapy in patient-reported outcomes & physician-reported toxicity.

  • Facebook
  • Instagram
  • YouTube
  • LinkedIn
Always-Here-Footer
Quick Links
  • Find a Doctor
  • Classes & Events
  • Clinical Trials
  • Patient Portals
  • Community Health Needs Assessment
  • Health Professionals
  • About Us
  • Health Resources
  • Newsroom
  • Contact Us
Hospitals & Locations
  • Willis-Knighton Medical Center
  • Willis-Knighton South and the Center for Women's Health
  • WK Bossier Health Center
  • WK Pierremont Health Center
  • WK Rehabilitation Institute
  • Progressive Care Center
  • Quick Care Urgent Care Centers
  • Project NeighborHealth
  • The Oaks of Louisiana
  • Fitness & Wellness Centers
  • WK Innovation Center
Services
  • Behavioral Medicine
  • Cancer Center
  • Children's Services
  • Emergency Services
  • Eye Services
  • Fitness & Wellness Centers
  • Heart & Vascular Institute
  • Home Health
  • Imaging – Radiology
  • Lab Services
  • Neonatal Intensive Care Unit (NICU)
  • Ornish Lifestyle Medicine
 
  • Obstetrics/Birthing
  • Occupational Medicine
  • Organ Transplant
  • Orthopedics
  • Pediatrics
  • Physical Medicine & Rehabilitation
  • Shots for Tots
  • Sports Medicine
  • Surgical Services
  • Urgent Care
  • Weight & Wellness Solutions
  • View a complete list of services
Billing & Insurance
  • Pay Your Bill Online
  • Insurances Accepted
  • Financial Assistance
Careers at WK
  • Benefits
  • Nursing Careers
  • Nursing Flex-Pool
  • Allied Health Careers
  • Non-Medical Careers
  • Physician & Advanced Practitioner Careers
©2021 Willis-Knighton Health System
  • Web Privacy Policy
  • Terms of Use
  • Notice of Privacy Practices
  • Find a Doctor Disclosures
  • Webmaster